These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 9049288)

  • 21. Percutaneous estradiol gel with an intrauterine levonorgestrel releasing device or natural progesterone in hormone replacement therapy.
    Suvanto-Luukkonen E; Sundström H; Penttinen J; Läärä E; Pramila S; Kauppila A
    Maturitas; 1997 Apr; 26(3):211-7. PubMed ID: 9147353
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Endometrial safety with a low-dose intrauterine levonorgestrel-releasing system after 3 years of estrogen substitution therapy.
    Wildemeersch D; Schacht E; Wildemeersch P; Calleweart K; Pylyser K; De Wever N
    Maturitas; 2004 May; 48(1):65-70. PubMed ID: 15223110
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Treatment of adenomyosis-associated menorrhagia with a levonorgestrel-releasing intrauterine device.
    Fedele L; Bianchi S; Raffaelli R; Portuese A; Dorta M
    Fertil Steril; 1997 Sep; 68(3):426-9. PubMed ID: 9314908
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Insulin-like growth factor-binding protein-1: a biochemical marker of endometrial response to progestin during hormone replacement therapy.
    Suvanto-Luukkonen E; Sundström H; Penttinen J; Kauppila A; Rutanen EM
    Maturitas; 1995 Nov; 22(3):255-62. PubMed ID: 8746884
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Morphological and functional features of endometrial decidualization following long-term intrauterine levonorgestrel delivery.
    Critchley HO; Wang H; Jones RL; Kelly RW; Drudy TA; Gebbie AE; Buckley CH; McNeilly AS; Glasier AF
    Hum Reprod; 1998 May; 13(5):1218-24. PubMed ID: 9647550
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Management of patients with non-atypical and atypical endometrial hyperplasia with a levonorgestrel-releasing intrauterine system: long-term follow-up.
    Wildemeersch D; Janssens D; Pylyser K; De Wever N; Verbeeck G; Dhont M; Tjalma W
    Maturitas; 2007 Jun; 57(2):210-3. PubMed ID: 17270370
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparing the effects of intrauterine progestin system and oral progestin on health-related quality of life and Kupperman index in hormone replacement therapy.
    Pirimoglu ZM; Ozyapi AG; Kars B; Buyukbayrak EE; Solak Y; Karsidag AY; Unal O; Turan MC
    J Obstet Gynaecol Res; 2011 Oct; 37(10):1376-81. PubMed ID: 21599801
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Intrauterine administration of levonorgestrel 5 and 10 microg/24 hours in perimenopausal hormone replacement therapy. A randomized clinical study during one year.
    Wollter-Svensson LO; Stadberg E; Andersson K; Mattsson LA; Odlind V; Persson I
    Acta Obstet Gynecol Scand; 1997 May; 76(5):449-54. PubMed ID: 9197448
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Progesterone/progestogen releasing intrauterine systems versus either placebo or any other medication for heavy menstrual bleeding.
    Lethaby AE; Cooke I; Rees M
    Cochrane Database Syst Rev; 2000; (2):CD002126. PubMed ID: 10796865
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A risk-benefit assessment of the levonorgestrel-releasing intrauterine system.
    Sturridge F; Guillebaud J
    Drug Saf; 1996 Dec; 15(6):430-40. PubMed ID: 8968696
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Serum levonorgestrel levels and endometrial thickness during extended use of the levonorgestrel-releasing intrauterine system.
    Hidalgo MM; Hidalgo-Regina C; Bahamondes MV; Monteiro I; Petta CA; Bahamondes L
    Contraception; 2009 Jul; 80(1):84-9. PubMed ID: 19501221
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Contraception with a novel 'frameless' intrauterine levonorgestrel-releasing drug delivery system: a pilot study.
    Wildemeersch D; Schacht E
    Eur J Contracept Reprod Health Care; 2000 Dec; 5(4):234-40. PubMed ID: 11245550
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Intrauterine or oral administration of levonorgestrel in combination with estradiol to perimenopausal women--effects on lipid metabolism during 12 months of treatment.
    Andersson K; Stadberg E; Mattsson LA; Rybo G; Samsioe G
    Int J Fertil Menopausal Stud; 1996; 41(5):476-83. PubMed ID: 8934257
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Intrauterine release of levonorgestrel--a new way of adding progestogen in hormone replacement therapy.
    Andersson K; Mattsson LA; Rybo G; Stadberg E
    Obstet Gynecol; 1992 Jun; 79(6):963-7. PubMed ID: 1579323
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Safety and comfort of long-term continuous combined transdermal estrogen and intrauterine levonorgestrel administration for postmenopausal hormone substitution - a review.
    Wildemeersch D
    Gynecol Endocrinol; 2016 Aug; 32(8):598-601. PubMed ID: 27117308
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Insulin sensitivity during postmenopausal hormone replacement with transdermal estradiol and intrauterine levonorgestrel.
    Raudaskoski T; Tomás C; Laatikainen T
    Acta Obstet Gynecol Scand; 1999 Jul; 78(6):540-5. PubMed ID: 10376866
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Levonorgestrel-releasing intrauterine system as an adjunct to estrogen for the treatment of menopausal symptoms--a review.
    Peled Y; Perri T; Pardo Y; Kaplan B
    Menopause; 2007; 14(3 Pt 1):550-4. PubMed ID: 17224852
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Endometrial protection from tamoxifen-stimulated changes by a levonorgestrel-releasing intrauterine system: a randomised controlled trial.
    Gardner FJ; Konje JC; Abrams KR; Brown LJ; Khanna S; Al-Azzawi F; Bell SC; Taylor DJ
    Lancet; 2000 Nov; 356(9243):1711-7. PubMed ID: 11095258
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Randomised comparative trial of the levonorgestrel intrauterine system and norethisterone for treatment of idiopathic menorrhagia.
    Irvine GA; Campbell-Brown MB; Lumsden MA; Heikkilä A; Walker JJ; Cameron IT
    Br J Obstet Gynaecol; 1998 Jun; 105(6):592-8. PubMed ID: 9647148
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Treatment of endometrial hyperplasia without atypia in peri- and postmenopausal women with a levonorgestrel intrauterine device.
    Haimovich S; Checa MA; Mancebo G; Fusté P; Carreras R
    Menopause; 2008; 15(5):1002-4. PubMed ID: 18451744
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.